IRON Stock Summary and Trading Ideas (Disc Medicine | NASDAQ:IRON)

Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Disc Medicine trades on the NASDAQ stock market under the symbol IRON.

As of March 5, 2026, IRON stock price declined to $60.34 with 807,633 million shares trading.

IRON has a beta of 1.52, meaning it tends to be more sensitive to market movements. IRON has a correlation of 0.17 to the broad based SPY ETF.

IRON has a market cap of $2.28 billion. This is considered a Mid Cap stock.

In the last 3 years, IRON traded as high as $99.50 and as low as $18.25.

The top ETF exchange traded funds that IRON belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.

IRON has underperformed the market in the last year with a price return of +9.0% while the SPY ETF gained +19.4%. IRON has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.7% and -6.4%, respectively, while the SPY returned -0.2% and -0.7%, respectively.

IRON support price is $58.44 and resistance is $63.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IRON shares will trade within this expected range on the day.